Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (131-140 of 210) with videos related to

Pageof 21
Sort By:
Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.
Nature Communications|August 30, 2024
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockadeMarie-Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysisMark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Pageof 21

Showing results (131-140 of 210) with videos related to

Sort By:
Pageof 21
Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.
Nature Communications|August 30, 2024
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockadeMarie-Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysisMark M Awad, Giulia C Leonardi, Sasha Kravets, et al.
The New England Journal of Medicine|June 4, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Mark M Awad, Ryohei Katayama, Michele McTigue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
JCO Precision Oncology|February 8, 2024
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non-Small-Cell Lung CancerAbdul Rafeh Naqash, Charalampos S Floudas, Etan Aber, et al.
JTO Clinical and Research Reports|April 20, 2026
Sotorasib in Advanced <i>KRAS</i> G12C-Mutated NSCLC: Results From the Global Expanded Access Program, Including Patients With Poor Performance Status and a History of CNS MetastasesSilvia Novello, Natalie Maimon Rabinovich, Jin-Yuan Shih, et al.
Cancer Discovery|March 29, 2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerLuc Friboulet, Nanxin Li, Ryohei Katayama, et al.
Pageof 21